secwatch.observer — SEC 8-K summary
======================================

Issuer:     DAVITA INC. (DVA)
CIK:        0000927066
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0001206774-24-000897
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DaVita appoints David P. Maughan as COO, Kidney Care; Staffieri becomes COO Emeritus
--------------------------------------------------------------------------------

- David P. Maughan appointed COO, DaVita Kidney Care, effective September 15, 2024, succeeding Michael D. Staffieri.
- Maughan previously SVP overseeing home and hospital services, HR, IT, marketing, and state government affairs.
- Employment agreement provides $725,000 base salary and 2024 target bonus of 100% of base salary earned.
- Severance includes benefits under DaVita Severance Plan; enhanced to 2-year base salary if Good Cause resignation within 2 years post-change-of-control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/927066/000120677424000897/0001206774-24-000897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/927066/000120677424000897/dva4379221-8k.htm
  HTML page:      https://secwatch.observer/filing/0001206774-24-000897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer